|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-7-2
|
|
pubmed:abstractText |
Strong overexpression of glucagonlike peptide-1 (GLP-1) receptors in human insulinoma provides an attractive target for imaging. The first clinical trials demonstrated that GLP-1 receptor SPECT/CT using [Lys(40)(Ahx [6-aminohexanoic acid]-DOTA-(111)In)NH(2)]-exendin-4 can localize hardly detectable insulinomas. However, [Lys(40)(Ahx-DOTA-(111)In)NH(2)]-exendin-4 imaging has drawbacks related to the use of (111)In in that it is costly and carries a relatively high radiation burden for the patient. The aim of this study was the preclinical evaluation of [Lys(40)(Ahx-DOTA-(68)Ga)NH(2)]-exendin-4 for PET/CT and [Lys(40)(Ahx-hydrazinonicotinamide [HYNIC]-(99m)Tc)NH(2)]-exendin-4 for SPECT/CT.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Gallium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Indicators and Reagents,
http://linkedlifedata.com/resource/pubmed/chemical/Indium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Glucagon,
http://linkedlifedata.com/resource/pubmed/chemical/Technetium Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Venoms,
http://linkedlifedata.com/resource/pubmed/chemical/exenatide,
http://linkedlifedata.com/resource/pubmed/chemical/glucagon-like peptide receptor
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1535-5667
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1059-67
|
|
pubmed:meshHeading |
pubmed-meshheading:20595511-Animals,
pubmed-meshheading:20595511-Cells, Cultured,
pubmed-meshheading:20595511-Dose-Response Relationship, Radiation,
pubmed-meshheading:20595511-Female,
pubmed-meshheading:20595511-Gallium Radioisotopes,
pubmed-meshheading:20595511-Indicators and Reagents,
pubmed-meshheading:20595511-Indium Radioisotopes,
pubmed-meshheading:20595511-Isotope Labeling,
pubmed-meshheading:20595511-Kidney,
pubmed-meshheading:20595511-Male,
pubmed-meshheading:20595511-Mice,
pubmed-meshheading:20595511-Mice, Transgenic,
pubmed-meshheading:20595511-Peptides,
pubmed-meshheading:20595511-Positron-Emission Tomography,
pubmed-meshheading:20595511-Radiopharmaceuticals,
pubmed-meshheading:20595511-Receptors, Glucagon,
pubmed-meshheading:20595511-Technetium Compounds,
pubmed-meshheading:20595511-Tissue Distribution,
pubmed-meshheading:20595511-Tomography, Emission-Computed,
pubmed-meshheading:20595511-Tomography, Emission-Computed, Single-Photon,
pubmed-meshheading:20595511-Venoms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
|
|
pubmed:affiliation |
Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
